Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)

References

• Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–27. doi:10.1038/s41574-019-0176-8.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109.
   PubMed Web of Science ®Google Scholar
• Vancells Lujan P, Vinas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. Nutrients. 2021;13(5):1442. doi:10.3390/nu13051442.
   PubMed Web of Science ®Google Scholar
• Aberg F, Byrne CD, Pirola CJ, Mannisto V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78(1):191–206. doi:10.1016/j.jhep.2022.08.030.
   PubMed Web of Science ®Google Scholar
• Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open. 2021;12:100149. doi:10.1016/j.metop.2021.100149.
   PubMedGoogle Scholar
• Proszkowiec-Weglarz M. Gastrointestinal anatomy and physiology. In: Colin G, Scanes S, editors. Sturkie’s Avian Physiology. Seventh ed. London, UK: Academic Press;2022. p. 485–527.
   Google Scholar
• Saez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. Int J Mol Sci. 2016;17(6):928. doi:10.3390/ijms17060928.
   PubMed Web of Science ®Google Scholar
• Quesada-Vazquez S, Bone C, Saha S, Triguero I, Colom-Pellicer M, Aragones G, Hildebrand F, Del Bas JM, Caimari A, Beraza N. et al. Microbiota dysbiosis and gut barrier dysfunction associated with non-alcoholic fatty liver disease are modulated by a specific metabolic cofactors’ combination. Int J Mol Sci. 2022;23(22):23. doi:10.3390/ijms232213675.
   Web of Science ®Google Scholar
• Gluchowski NL, Becuwe M, Walther TC, Farese RV Jr. Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2017;14(6):343–55. doi:10.1038/nrgastro.2017.32.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):434–41. doi:10.1007/s00535-013-0758-5.
   PubMed Web of Science ®Google Scholar
• Hong T, Chen Y, Li X, Lu Y. The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD. Oxid Med Cell Longev. 2021;2021:6889533. doi:10.1155/2021/6889533.
   PubMed Web of Science ®Google Scholar
• Spahis S, Delvin E, Borys JM, Levy E. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal. 2017;26(10):519–41. doi:10.1089/ars.2016.6776.
   PubMed Web of Science ®Google Scholar
• Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27–42. doi:10.1016/j.addr.2017.05.007.
   PubMed Web of Science ®Google Scholar
• Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875. doi:10.3390/cells9040875.
   PubMed Web of Science ®Google Scholar
• Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245(2):96–108. doi:10.1177/1535370219898141.
   PubMed Web of Science ®Google Scholar
• Leigh SJ, Morris MJ. Diet, inflammation and the gut microbiome: mechanisms for obesity-associated cognitive impairment. Biochim Biophys Acta Mol Basis Dis. 2020;1866(6):165767. doi:10.1016/j.bbadis.2020.165767.
   PubMed Web of Science ®Google Scholar
• Quesada-Vazquez S, Aragones G, Del Bas JM, Escoté X. Diet, gut microbiota and non-alcoholic fatty liver disease: three parts of the same axis. Cells. 2020;9(1):176. doi:10.3390/cells9010176.
   PubMed Web of Science ®Google Scholar
• Kiela PR, Ghishan FK. Physiology of intestinal absorption and secretion. Best Pract Res Clin Gastroenterol. 2016;30(2):145–59. doi:10.1016/j.bpg.2016.02.007.
   PubMed Web of Science ®Google Scholar
• Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667–85. doi:10.1038/nri3738.
   PubMed Web of Science ®Google Scholar
• Shaker A, Rubin DC. Intestinal stem cells and epithelial–mesenchymal interactions in the crypt and stem cell niche. Transl Res. 2010;156(3):180–187. doi:10.1016/j.trsl.2010.06.003.
   PubMed Web of Science ®Google Scholar
• Farre R, Fiorani M, Abdu Rahiman S, Matteoli G. Intestinal permeability, inflammation and the role of nutrients. Nutrients. 2020;12(4):12. doi:10.3390/nu12041185.
   Web of Science ®Google Scholar
• Liu S, Song P, Sun F, Ai S, Hu Q, Guan W, Wang M. The concept revolution of gut barrier: from epithelium to endothelium. Int Rev Immunol. 2021;40(6):401–408. doi:10.1080/08830185.2020.1841185.
   PubMed Web of Science ®Google Scholar
• Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11(9):821–34. doi:10.1080/17474124.2017.1343143.
   PubMed Web of Science ®Google Scholar
• Hansson GC. Mucins and the microbiome. Annu Rev Biochem. 2020;89(1):769–93. doi:10.1146/annurev-biochem-011520-105053.
   PubMedGoogle Scholar
• Bansil R, Turner BS. The biology of mucus: composition, synthesis and organization. Adv Drug Deliv Rev. 2018;124:3–15. doi:10.1016/j.addr.2017.09.023.
   PubMed Web of Science ®Google Scholar
• Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. Tissue Barriers. 2015;3(1–2):e982426. doi:10.4161/21688370.2014.982426.
   PubMedGoogle Scholar
• Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A, van der Post S, Svensson F, Rodríguez‐Piñeiro AM, Nyström EEL. et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 2014;260(1):8–20. doi:10.1111/imr.12182.
   PubMed Web of Science ®Google Scholar
• Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A. 2008;105(39):15064–9. doi:10.1073/pnas.0803124105.
   PubMed Web of Science ®Google Scholar
• Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 2001;280(5):G922–9. doi:10.1152/ajpgi.2001.280.5.G922.
   PubMed Web of Science ®Google Scholar
• Vanuytsel T, Tack J, Farre R. The role of intestinal permeability in gastrointestinal disorders and Current methods of evaluation. Front Nutr. 2021;8:717925. doi:10.3389/fnut.2021.717925.
   PubMed Web of Science ®Google Scholar
• Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993;123(6):1777–1788. doi:10.1083/jcb.123.6.1777.
   PubMed Web of Science ®Google Scholar
• Powell K. Sticking it out with tight junctions. J Cell Biol. 2005;171(6):916–7. doi:10.1083/jcb1716fta1.
   Web of Science ®Google Scholar
• Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Experimental & Molecular Medicine. 2018;50(8):1–9. doi:10.1038/s12276-018-0126-x.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol. 2003;81(1):1–44. doi:10.1016/S0079-6107(02)00037-8.
   PubMed Web of Science ®Google Scholar
• Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. 2011;73(1):283–309. doi:10.1146/annurev-physiol-012110-142150.
   PubMedGoogle Scholar
• Otani T, Furuse M. Tight junction structure and function revisited. Trends Cell Biol. 2020;30(10):805–17. doi:10.1016/j.tcb.2020.08.004.
   PubMed Web of Science ®Google Scholar
• Spadoni I, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A, Caprioli F, Bottiglieri L, Oldani A, Viale G. et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350(6262):830–4. doi:10.1126/science.aad0135.
   PubMed Web of Science ®Google Scholar
• Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L. et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71(6):1216–28. doi:10.1016/j.jhep.2019.08.005.
   PubMed Web of Science ®Google Scholar
• Di Tommaso N, Santopaolo F, Gasbarrini A, Ponziani FR. The gut–vascular barrier as a new protagonist in intestinal and extraintestinal diseases. Int J Mol Sci. 2023;24(2):24. doi:10.3390/ijms24021470.
   Web of Science ®Google Scholar
• Herrnberger L, Ebner K, Junglas B, Tamm ER. The role of plasmalemma vesicle-associated protein (PLVAP) in endothelial cells of Schlemm’s canal and ocular capillaries. Exp Eye Res. 2012;105:27–33. doi:10.1016/j.exer.2012.09.011.
   PubMed Web of Science ®Google Scholar
• Bosma EK, van Noorden CJF, Schlingemann RO, Klaassen I. The role of plasmalemma vesicle-associated protein in pathological breakdown of blood–brain and blood–retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema. Fluids Barriers CNS. 2018;15(1):24. doi:10.1186/s12987-018-0109-2.
   PubMedGoogle Scholar
• Brescia P, Rescigno M. The gut vascular barrier: a new player in the gut–liver–brain axis. Trends Mol Med. 2021;27(9):844–855. doi:10.1016/j.molmed.2021.06.007.
   PubMed Web of Science ®Google Scholar
• Takiishi T, Fenero CIM, Camara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers. 2017;5(4):e1373208. doi:10.1080/21688370.2017.1373208.
   PubMed Web of Science ®Google Scholar
• Hu MD, Ethridge AD, Lipstein R, Kumar S, Wang Y, Jabri B, Turner JR, Edelblum KL. Epithelial IL-15 is a critical regulator of γδ intraepithelial lymphocyte motility within the intestinal mucosa. J Immunol. 2018;201(2):747–756. doi:10.4049/jimmunol.1701603.
   PubMed Web of Science ®Google Scholar
• Hyun J, Romero L, Riveron R, Flores C, Kanagavelu S, Chung KD, Alonso A, Sotolongo J, Ruiz J, Manukyan A. et al. Human intestinal epithelial cells express interleukin-10 through toll-like receptor 4-mediated epithelial-macrophage crosstalk. J Innate Immun. 2015;7(1):87–101. doi:10.1159/000365417.
   PubMed Web of Science ®Google Scholar
• Yap YA, Marino E. An insight into the intestinal web of mucosal immunity, microbiota, and diet in inflammation. Front Immunol. 2018;9:2617. doi:10.3389/fimmu.2018.02617.
   PubMed Web of Science ®Google Scholar
• Buckley A, Turner JR. Cell biology of tight junction barrier regulation and mucosal disease. Cold Spring Harb Perspect Biol. 2018;10(1):10. doi:10.1101/cshperspect.a029314.
   Web of Science ®Google Scholar
• Riedel S, Pheiffer C, Johnson R, Louw J, Muller CJF. Intestinal barrier function and immune homeostasis are missing links in obesity and type 2 diabetes development. Front Endocrinol (Lausanne). 2021;12:833544. doi:10.3389/fendo.2021.833544.
   PubMed Web of Science ®Google Scholar
• Fan H, Wang A, Wang Y, Sun Y, Han J, Chen W, Wang S, Wu Y, Lu Y. Innate lymphoid cells: regulators of gut barrier function and immune homeostasis. J Immunol Res. 2019;2019:1–15. doi:10.1155/2019/2525984.
   Web of Science ®Google Scholar
• Layhadi JA, Shamji MH. Uncovering the immunological properties of isolated lymphoid follicles. Allergy. 2021;76(4):1292–3. doi:10.1111/all.14598.
   PubMed Web of Science ®Google Scholar
• Knoop KA, Newberry RD. Isolated lymphoid follicles are dynamic reservoirs for the induction of intestinal IgA. Front Immunol. 2012;3:84. doi:10.3389/fimmu.2012.00084.
   PubMed Web of Science ®Google Scholar
• Pietrzak B, Tomela K, Olejnik-Schmidt A, Mackiewicz A, Schmidt M. Secretory IgA in intestinal mucosal secretions as an adaptive barrier against microbial cells. Int J Mol Sci. 2020;21(23):21. doi:10.3390/ijms21239254.
   Web of Science ®Google Scholar
• Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP. et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7. doi:10.1038/nature11053.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Whitley CS, Haribabu B, Jala VR. Regulation of intestinal barrier function by microbial metabolites. Cell Mol Gastroenterol Hepatol. 2021;11(5):1463–82. doi:10.1016/j.jcmgh.2021.02.007.
   PubMed Web of Science ®Google Scholar
• Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. doi:10.1371/journal.pbio.1002533.
   PubMed Web of Science ®Google Scholar
• Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–36. doi:10.1042/BCJ20160510.
   PubMed Web of Science ®Google Scholar
• Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148(6):1258–70. doi:10.1016/j.cell.2012.01.035.
   PubMed Web of Science ®Google Scholar
• Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492–506. doi:10.1038/s41422-020-0332-7.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele M. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. doi:10.3390/microorganisms7010014.
   PubMed Web of Science ®Google Scholar
• Caballero-Flores G, Pickard JM, Nunez G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nat Rev Microbiol. 2022;21(6):347–360. doi:10.1038/s41579-022-00833-7.
   PubMed Web of Science ®Google Scholar
• Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473–93. doi:10.1007/s00018-018-2943-4.
   PubMed Web of Science ®Google Scholar
• Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, Tuohy K. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24. doi:10.1007/s00394-017-1445-8.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Cintoni M, Raoul P, Lopetuso LR, Scaldaferri F, Pulcini G, Miggiano GA, Gasbarrini A, Mele MC. Food components and dietary habits: keys for a healthy gut microbiota composition. Nutrients. 2019;11(10):2393. doi:10.3390/nu11102393.
   PubMed Web of Science ®Google Scholar
• Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome. 2019;7(1):91. doi:10.1186/s40168-019-0704-8.
   PubMed Web of Science ®Google Scholar
• Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012;4(8):1095–119. doi:10.3390/nu4081095.
   PubMed Web of Science ®Google Scholar
• Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J. et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135. doi:10.1038/s41392-022-00974-4.
   PubMed Web of Science ®Google Scholar
• Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr. 2022;76(4):489–501. doi:10.1038/s41430-021-00991-6.
   PubMed Web of Science ®Google Scholar
• Sharma R, Schumacher U, Ronaasen V, Coates M. Rat intestinal mucosal responses to a microbial flora and different diets. Gut. 1995;36(2):209–14. doi:10.1136/gut.36.2.209.
   PubMed Web of Science ®Google Scholar
• Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO, Roos S, Holm L, Phillipson M. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol. 2011;300(2):G327–33. doi:10.1152/ajpgi.00422.2010.
   PubMed Web of Science ®Google Scholar
• Herath M, Hosie S, Bornstein JC, Franks AE, Hill-Yardin EL. The role of the gastrointestinal mucus system in intestinal homeostasis: implications for neurological disorders. Front Cell Infect Microbiol. 2020;10:248. doi:10.3389/fcimb.2020.00248.
   PubMed Web of Science ®Google Scholar
• Makki K, Deehan EC, Walter J, Backhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23(6):705–15. doi:10.1016/j.chom.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Vinolo MA, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011;22(9):849–55. doi:10.1016/j.jnutbio.2010.07.009.
   PubMed Web of Science ®Google Scholar
• Miao W, Wu X, Wang K, Wang W, Wang Y, Li Z, Liu J, Li L, Peng L. Sodium butyrate promotes reassembly of tight junctions in caco-2 monolayers involving inhibition of MLCK/MLC2 pathway and phosphorylation of PKCβ2. Int J Mol Sci. 2016;17(10):1696. doi:10.3390/ijms17101696.
   PubMed Web of Science ®Google Scholar
• Cunningham KE, Turner JR. Myosin light chain kinase: pulling the strings of epithelial tight junction function. Ann N Y Acad Sci. 2012;1258(1):34–42. doi:10.1111/j.1749-6632.2012.06526.x.
   PubMedGoogle Scholar
• Ruff WE, Greiling TM, Kriegel MA. Host–microbiota interactions in immune-mediated diseases. Nat Rev Microbiol. 2020;18(9):521–538. doi:10.1038/s41579-020-0367-2.
   PubMed Web of Science ®Google Scholar
• Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209. doi:10.1016/j.jhep.2013.07.044.
   PubMed Web of Science ®Google Scholar
• Ray A, Cot M, Puzo G, Gilleron M, Nigou J. Bacterial cell wall macroamphiphiles: pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. Biochimie. 2013;95(1):33–42. doi:10.1016/j.biochi.2012.06.007.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21(4):317–37. doi:10.1093/intimm/dxp017.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Signaling to NF-κB by toll-like receptors. Trends Mol Med. 2007;13(11):460–469. doi:10.1016/j.molmed.2007.09.002.
   PubMed Web of Science ®Google Scholar
• Volta U, Bonazzi C, Bianchi FB, Baldoni AM, Zoli M, Pisi E. IgA antibodies to dietary antigens in liver cirrhosis. Ric Clin Lab. 1987;17(3):235–42. doi:10.1007/BF02912537.
   PubMedGoogle Scholar
• Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–24. doi:10.1053/j.gastro.2014.01.020.
   PubMed Web of Science ®Google Scholar
• Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65(12):2035–44. doi:10.1136/gutjnl-2016-312729.
   PubMed Web of Science ®Google Scholar
• Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A. Intestinal permeability in the pathogenesis of liver damage: from non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol. 2019;25(33):4814–4834. doi:10.3748/wjg.v25.i33.4814.
   PubMed Web of Science ®Google Scholar
• Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50(8):1509–20. doi:10.1194/jlr.R900007-JLR200.
   PubMed Web of Science ®Google Scholar
• Nakade Y, Kitano R, Sakamoto K, Kimoto S, Yamauchi T, Inoue T, Kobayashi Y, Ohashi T, Sumida Y, Ito K. et al. Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. PloS One. 2021;16(2):e0247303. doi:10.1371/journal.pone.0247303.
   PubMed Web of Science ®Google Scholar
• Aranha MM, Cortez-Pinto H, Costa A, da Silva IB, Camilo ME, de Moura MC, Rodrigues CMP. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20(6):519–525. doi:10.1097/MEG.0b013e3282f4710a.
   PubMed Web of Science ®Google Scholar
• Kodama M, Kanno K, Kishikawa N, Takei H, Nittono H, Tazuma S. Decrease in major secondary bile acid, hyodeoxycholic acid, was the main alteration in hepatic bile acid compositions in a hypertensive nonalcoholic fatty liver disease model. J Hepato-Biliary-Pancreat Sci. 2019;26:557–567. doi:10.1002/jhbp.678.
   PubMed Web of Science ®Google Scholar
• Lin H, An Y, Tang H, Wang Y. Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat model. J Agric Food Chem. 2019;67(13):3624–32. doi:10.1021/acs.jafc.9b00249.
   PubMed Web of Science ®Google Scholar
• Fuchs M. Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids. 2012;2012:934396. doi:10.1155/2012/934396.
   PubMedGoogle Scholar
• Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4523–4530. doi:10.1073/pnas.1006734107.
   PubMed Web of Science ®Google Scholar
• Parseus A, Sommer N, Sommer F, Caesar R, Molinaro A, Stahlman M, Greiner TU, Perkins R, Bäckhed F. Microbiota-induced obesity requires farnesoid X receptor. Gut. 2017;66(3):429–437. doi:10.1136/gutjnl-2015-310283.
   PubMed Web of Science ®Google Scholar
• Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225–35. doi:10.1016/j.cmet.2013.01.003.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Lu Y, Li XY. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2015;36(1):44–50. doi:10.1038/aps.2014.116.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397–411. doi:10.1038/s41575-018-0011-z.
   PubMed Web of Science ®Google Scholar
• Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol. 2016;8(32):1354–69. doi:10.4254/wjh.v8.i32.1354.
   PubMedGoogle Scholar
• Liu L, Yin M, Gao J, Yu C, Lin J, Wu A, Zhu J, Xu C, Liu X. Intestinal barrier function in the pathogenesis of nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2023;11(2):452–458. doi:10.14218/JCTH.2022.00089.
   PubMed Web of Science ®Google Scholar
• Farre R, Vicario M. Abnormal Barrier Function in Gastrointestinal Disorders. Handb Exp Pharmacol. 2017;239:193–217.
   PubMedGoogle Scholar
• Xin D, Zong-Shun L, Bang-Mao W, Lu Z. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease. Hepatogastroenterology. 2014;61:136–140.
   PubMedGoogle Scholar
• Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, Smith T, Neish AS, Li H, Tan S. et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology. 2016;151(4):733–46 e12. doi:10.1053/j.gastro.2016.06.022.
   PubMed Web of Science ®Google Scholar
• Cui Y, Wang Q, Chang R, Zhou X, Xu C. Intestinal barrier function–non-alcoholic fatty liver disease interactions and possible role of gut microbiota. J Agric Food Chem. 2019;67(10):2754–2762. doi:10.1021/acs.jafc.9b00080.
   PubMed Web of Science ®Google Scholar
• Pellicciotta M, Rigoni R, Falcone EL, Holland SM, Villa A, Cassani B. The microbiome and immunodeficiencies: lessons from rare diseases. J Autoimmun. 2019;98:132–48. doi:10.1016/j.jaut.2019.01.008.
   PubMed Web of Science ®Google Scholar
• Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158–72. doi:10.1053/j.gastro.2012.09.008.
   PubMed Web of Science ®Google Scholar
• McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60(5):1055–62. doi:10.1016/j.jhep.2014.01.010.
   PubMed Web of Science ®Google Scholar
• Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017;551(7680):340–5. doi:10.1038/nature24302.
   PubMed Web of Science ®Google Scholar
• Karl M, Hasselwander S, Zhou Y, Reifenberg G, Kim YO, Park KS, Ridder DA, Wang X, Seidel E, Hövelmeyer N. et al. Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease. Hepatology. 2022;76(4):1135–49. doi:10.1002/hep.32428.
   PubMed Web of Science ®Google Scholar
• Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–77. doi:10.1016/j.jhep.2019.10.003.
   PubMed Web of Science ®Google Scholar
• Wilcz-Villega EM, McClean S, O’Sullivan MA. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. Am J Gastroenterol. 2013;108(7):1140–51. doi:10.1038/ajg.2013.92.
   PubMed Web of Science ®Google Scholar
• Potts RA, Tiffany CM, Pakpour N, Lokken KL, Tiffany CR, Cheung K, Tsolis RM, Luckhart S. Mast cells and histamine alter intestinal permeability during malaria parasite infection. Immunobiology. 2016;221(3):468–474. doi:10.1016/j.imbio.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Tomita K, Teratani T, Yokoyama H, Suzuki T, Irie R, Ebinuma H, Saito H, Hokari R, Miura S, Hibi T. et al. Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig Dis Sci. 2011;56(12):3648–54. doi:10.1007/s10620-011-1771-2.
   PubMed Web of Science ®Google Scholar
• Fang J, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH, Yu WY. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018. doi:10.3389/fcimb.2022.997018.
   PubMed Web of Science ®Google Scholar
• Tokuhara D. Role of the gut microbiota in regulating non-alcoholic fatty liver disease in children and adolescents. Front Nutr. 2021;8:700058. doi:10.3389/fnut.2021.700058.
   PubMed Web of Science ®Google Scholar
• Khan MJ, Gerasimidis K, Edwards CA, Shaikh MG. Role of gut microbiota in the aetiology of obesity: proposed mechanisms and review of the literature. J Obes. 2016;2016:7353642. doi:10.1155/2016/7353642.
   PubMed Web of Science ®Google Scholar
• Chakaroun RM, Massier L, Kovacs P. Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders? Nutrients. 2020;12(4):12. doi:10.3390/nu12041082.
   Web of Science ®Google Scholar
• Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB, Ahn J. A taxonomic signature of obesity in a large study of American adults. Sci Rep. 2018;8(1):9749. doi:10.1038/s41598-018-28126-1.
   PubMedGoogle Scholar
• Palmas V, Pisanu S, Madau V, Casula E, Deledda A, Cusano R, Uva P, Vascellari S, Loviselli A, Manzin A. et al. Gut microbiota markers associated with obesity and overweight in Italian adults. Sci Rep. 2021;11(1):5532. doi:10.1038/s41598-021-84928-w.
   PubMed Web of Science ®Google Scholar
• Kim MH, Yun KE, Kim J, Park E, Chang Y, Ryu S, Kim H-L, Kim H-N. Gut microbiota and metabolic health among overweight and obese individuals. Sci Rep. 2020;10(1):19417. doi:10.1038/s41598-020-76474-8.
   PubMed Web of Science ®Google Scholar
• Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P, Balamurugan R. The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients. 2020;12(5):1474. doi:10.3390/nu12051474.
   PubMed Web of Science ®Google Scholar
• Duarte SMB, Stefano JT, Oliveira CP. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann Hepatol. 2019;18(3):416–21. doi:10.1016/j.aohep.2019.04.006.
   PubMed Web of Science ®Google Scholar
• Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3. doi:10.1038/4441022a.
   PubMed Web of Science ®Google Scholar
• Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–15723. doi:10.1073/pnas.0407076101.
   PubMed Web of Science ®Google Scholar
• Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature. 2012;487(7405):104–108. doi:10.1038/nature11225.
   PubMed Web of Science ®Google Scholar
• Quesada-Vazquez S, Colom-Pellicer M, Navarro-Masip E, Aragones G, Del Bas JM, Caimari A, Escoté X. Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice. Nutrients. 2021;13(10):3532. doi:10.3390/nu13103532.
   PubMed Web of Science ®Google Scholar
• Zhang C, Bjornson E, Arif M, Tebani A, Lovric A, Benfeitas R, Ozcan M, Juszczak K, Kim W, Kim JT. et al. The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease. Mol Syst Biol. 2020;16(4):e9495. doi:10.15252/msb.209495.
   PubMed Web of Science ®Google Scholar
• Mardinoglu A, Ural D, Zeybel M, Yuksel HH, Uhlen M, Boren J. The potential use of metabolic cofactors in treatment of NAFLD. Nutrients. 2019;11(7):11. doi:10.3390/nu11071578.
   Web of Science ®Google Scholar
• Hayashi T, Yamashita T, Takahashi T, Tabata T, Watanabe H, Gotoh Y, Shinohara M, Kami K, Tanaka H, Matsumoto K. et al. Uncovering the role of gut microbiota in amino acid metabolic disturbances in heart failure through metagenomic analysis. Front Cardiovasc Med. 2021;8:789325. doi:10.3389/fcvm.2021.789325.
   PubMed Web of Science ®Google Scholar
• Niu YC, Feng RN, Hou Y, Li K, Kang Z, Wang J, Sun C-H, Li Y. Histidine and arginine are associated with inflammation and oxidative stress in obese women. Br J Nutr. 2012;108(1):57–61. doi:10.1017/S0007114511005289.
   PubMed Web of Science ®Google Scholar
• Quesada-Vazquez S, Castells-Nobau A, Latorre J, Oliveras-Canellas N, Puig-Parnau I, Tejera N, Tobajas Y, Baudin J, Hildebrand F, Beraza N. et al. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. Cell Rep Med. 2023;4(12):101341. doi:10.1016/j.xcrm.2023.101341.
   PubMedGoogle Scholar
• Ferreira DF, Fiamoncini J, Prist IH, Ariga SK, de Souza HP, de Lima TM. Novel role of TLR4 in NAFLD development: modulation of metabolic enzymes expression. Biochim Biophys Acta. 2015;1851(10):1353–1359. doi:10.1016/j.bbalip.2015.07.002.
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–609. doi:10.1002/hep.26093.
   PubMed Web of Science ®Google Scholar
• Hyun J, Han J, Lee C, Yoon M, Jung Y. Pathophysiological aspects of alcohol metabolism in the liver. Int J Mol Sci. 2021;22(11):22. doi:10.3390/ijms22115717.
   Web of Science ®Google Scholar
• Chen X, Zhang Z, Li H, Zhao J, Wei X, Lin W, Zhao X, Jiang A, Yuan J. Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35(11):2009–2019. doi:10.1111/jgh.15027.
   PubMed Web of Science ®Google Scholar
• Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol. 2017;23(36):6549–70. doi:10.3748/wjg.v23.i36.6549.
   PubMed Web of Science ®Google Scholar
• Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic Fatty Liver Disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022;23(24):23. doi:10.3390/ijms232415489.
   Web of Science ®Google Scholar
• Hajdarevic B, Vehabovic I, Catic T, Masic I. The role of diet therapy in the treatment of liver disease. Mater Sociomed. 2020;32(3):200–206. doi:10.5455/msm.2020.32.200-206.
   PubMedGoogle Scholar
• Wegh CAM, Schoterman MHC, Vaughan EE, Belzer C, Benninga MA. The effect of fiber and prebiotics on children’s gastrointestinal disorders and microbiome. Expert Rev Gastroenterol Hepatol. 2017;11(11):1031–45. doi:10.1080/17474124.2017.1359539.
   PubMed Web of Science ®Google Scholar
• Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8. doi:10.1126/science.1208344.
   PubMed Web of Science ®Google Scholar
• Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72. doi:10.2337/db06-1491.
   PubMed Web of Science ®Google Scholar
• Sonnenburg JL, Backhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64. doi:10.1038/nature18846.
   PubMed Web of Science ®Google Scholar
• Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25. doi:10.3389/fendo.2020.00025.
   PubMed Web of Science ®Google Scholar
• Nobili V, Carter-Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver disease. BMC Med. 2011;9(1):70. doi:10.1186/1741-7015-9-70.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu X, Yu X, Novak P, Gui Q, Yin K. Enhancing intestinal barrier efficiency: a novel metabolic diseases therapy. Front Nutr. 2023;10:1120168. doi:10.3389/fnut.2023.1120168.
   PubMed Web of Science ®Google Scholar
• Cigrovski BM, Bilic-Curcic I, Mrzljak A, Cigrovski V. NAFLD and physical exercise: ready, steady, go! Front Nutr. 2021;8:734859. doi:10.3389/fnut.2021.734859.
   PubMed Web of Science ®Google Scholar
• Ma Q, Ye J, Shao C, Lin Y, Wu T, Zhong B. Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Ther Adv Endocrinol Metab. 2022;13:20420188221122426. doi:10.1177/20420188221122426.
   Web of Science ®Google Scholar
• Clauss M, Gerard P, Mosca A, Leclerc M. Interplay between exercise and gut microbiome in the context of human health and performance. Front Nutr. 2021;8:637010. doi:10.3389/fnut.2021.637010.
   PubMed Web of Science ®Google Scholar
• Feng V, Bawa KK, Marzolini S, Kiss A, Oh P, Herrmann N, Lanctôt KL, Gallagher D. Impact of 12-week exercise program on biomarkers of gut barrier integrity in patients with coronary artery disease. PloS One. 2021;16(11):e0260165. doi:10.1371/journal.pone.0260165.
   PubMed Web of Science ®Google Scholar
• Evans CC, LePard KJ, Kwak JW, Stancukas MC, Laskowski S, Dougherty J, Moulton L, Glawe A, Wang Y, Leone V. et al. Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity. PloS One. 2014;9(3):e92193. doi:10.1371/journal.pone.0092193.
   PubMed Web of Science ®Google Scholar
• Carbajo-Pescador S, Porras D, Garcia-Mediavilla MV, Martinez-Florez S, Juarez-Fernandez M, Cuevas MJ, Mauriz JL, González-Gallego J, Nistal E, Sánchez-Campos S. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver axis crosstalk in an in vivo model of early obesity and NAFLD. Disease Models & Mechanisms. 2019;12. doi:10.1242/dmm.039206.
   PubMed Web of Science ®Google Scholar
• Hoffman-Goetz L, Quadrilatero J. Treadmill exercise in mice increases intestinal lymphocyte loss via apoptosis. Acta Physiol Scand. 2003;179(3):289–97. doi:10.1046/j.1365-201X.2003.01176.x.
   PubMedGoogle Scholar
• Sohail MU, Yassine HM, Sohail A, Thani AAA. Impact of physical exercise on gut microbiome, inflammation, and the pathobiology of metabolic disorders. Rev Diabet Stud. 2019;15(1):35–48. doi:10.1900/RDS.2019.15.35.
   PubMedGoogle Scholar
• Campbell SC, Wisniewski PJ, Noji M, McGuinness LR, Haggblom MM, Lightfoot SA, Joseph LB, Kerkhof LJ. The effect of diet and exercise on intestinal integrity and microbial diversity in mice. PloS One. 2016;11(3):e0150502. doi:10.1371/journal.pone.0150502.
   PubMed Web of Science ®Google Scholar
• Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC, Wahlström A, Ashby JW. et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33(8):1671–84 e4. doi:10.1016/j.cmet.2021.06.012.
   PubMed Web of Science ®Google Scholar
• Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VWS, Greenbloom S, Jayakumar S. et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology. 2020;72(1):58–71. doi:10.1002/hep.31205.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, Lee J, Wagner B, Smith ND, Chen HC, Lawitz EJ. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol. 2021;75(1):25–33. doi:10.1016/j.jhep.2021.01.047.
   PubMedGoogle Scholar
• Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N. et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol. 2018;24(2):195–210. doi:10.3748/wjg.v24.i2.195.
   PubMed Web of Science ®Google Scholar
• Ding L, Yang Q, Zhang E, Wang Y, Sun S, Yang Y, Tian T, Ju Z, Jiang L, Wang X. et al. Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice. Acta Pharm Sin B. 2021;11(6):1541–54. doi:10.1016/j.apsb.2021.03.038.
   PubMed Web of Science ®Google Scholar
• Kumar A, Al-Hassi HO, Steed H, Phipps O, Brookes MJ. Bile acids and the microbiome: making sense of this dynamic relationship in their role and management in Crohn’s disease. Can J Gastroenterol Hepatol. 2022;2022:8416578. doi:10.1155/2022/8416578.
   PubMed Web of Science ®Google Scholar
• Bilal M, Ashraf S, Zhao X. Dietary component-induced inflammation and its amelioration by prebiotics, probiotics, and synbiotics. Front Nutr. 2022;9:931458. doi:10.3389/fnut.2022.931458.
   PubMed Web of Science ®Google Scholar
• Xing W, Gao W, Lv X, Zhao Z, Mao G, Dong X, Zhang Z. The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Front Nutr. 2022;9:1024678. doi:10.3389/fnut.2022.1024678.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu AL, Li ZC, Li Y, Xu SF, Sang HC, Zhi F. Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice. Diabetes Metab J. 2020;44(2):336–348. doi:10.4093/dmj.2019.0042.
   PubMed Web of Science ®Google Scholar
• El-Din SH S, Salem MB, El-Lakkany NM, Hammam OA, Nasr SM, Okasha H, Ahmed LA, Saleh S, Botros SS. Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Hum Exp Toxicol. 2021;40(9):1496–1509. doi:10.1177/0960327121999445.
   PubMed Web of Science ®Google Scholar
• Mohamad nor MH, Ayob N, Mokhtar NM, Raja Ali RA, Tan GC, Wong Z, Shafiee NH, Wong YP, Mustangin M, Nawawi KNM. et al. The effect of probiotics (MCP® BCMC® strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients. 2021;13(9):3192. doi:10.3390/nu13093192.
   PubMed Web of Science ®Google Scholar
• Gou HZ, Zhang YL, Ren LF, Li ZJ, Zhang L. How do intestinal probiotics restore the intestinal barrier? Front Microbiol. 2022;13:929346. doi:10.3389/fmicb.2022.929346.
   PubMed Web of Science ®Google Scholar
• Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P. PPAR as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55(9):1341–1349. doi:10.1136/gut.2006.093484.
   PubMed Web of Science ®Google Scholar
• Ahl D, Liu H, Schreiber O, Roos S, Phillipson M, Holm L. Lactobacillus reuteri increases mucus thickness and ameliorates dextran sulphate sodium-induced colitis in mice. Acta Physiol (Oxf). 2016;217(4):300–310. doi:10.1111/apha.12695.
   PubMed Web of Science ®Google Scholar
• Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, Paillarse J-M, Chêne L, Blottière HM, Gérard P. et al. Fecal microbiota transplant from human to mice gives insights into the role of the gut microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). Microorganisms. 2021;9(1):199. doi:10.3390/microorganisms9010199.
   PubMed Web of Science ®Google Scholar
• Zoll J, Read MN, Heywood SE, Estevez E, Marshall JPS, Kammoun HL, Allen TL, Holmes AJ, Febbraio MA, Henstridge DC. et al. Fecal microbiota transplantation from high caloric-fed donors alters glucose metabolism in recipient mice, independently of adiposity or exercise status. Am J Physiol Endocrinol Metab. 2020;319(1):E203–E16. doi:10.1152/ajpendo.00037.2020.
   PubMed Web of Science ®Google Scholar
• Perez-Matute P, Iniguez M, de Toro M, Recio-Fernandez E, Oteo JA. Autologous fecal transplantation from a lean state potentiates caloric restriction effects on body weight and adiposity in obese mice. Sci Rep. 2020;10(1):9388. doi:10.1038/s41598-020-64961-x.
   PubMed Web of Science ®Google Scholar
• Lai ZL, Tseng CH, Ho HJ, Cheung CKY, Lin JY, Chen YJ, Cheng F-C, Hsu Y-C, Lin J-T, El-Omar EM. et al. Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice. Sci Rep. 2018;8(1):15625. doi:10.1038/s41598-018-33893-y.
   PubMedGoogle Scholar
• Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan J-G. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017;7(1):1529. doi:10.1038/s41598-017-01751-y.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569–580. doi:10.1136/gutjnl-2016-313017.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Bibbo S, Porcari S, Settanni CR, Giambo F, Curta AR, Quaranta G, Scaldaferri F, Masucci L, Sanguinetti M. et al. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes. 2021;13(1):1994834. doi:10.1080/19490976.2021.1994834.
   PubMed Web of Science ®Google Scholar
• Leong KSW, Jayasinghe TN, Wilson BC, Derraik JGB, Albert BB, Chiavaroli V, Svirskis DM, Beck KL, Conlon CA, Jiang Y. et al. Effects of fecal microbiome transfer in adolescents with obesity: the gut bugs randomized controlled trial. JAMA Netw Open. 2020;3(12):e2030415. doi:10.1001/jamanetworkopen.2020.30415.
   PubMed Web of Science ®Google Scholar
• Yu EW, Gao L, Stastka P, Cheney MC, Mahabamunuge J, Torres Soto M, Ford CB, Bryant JA, Henn MR, Hohmann EL. et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051. doi:10.1371/journal.pmed.1003051.
   PubMed Web of Science ®Google Scholar
• Xue L, Deng Z, Luo W, He X, Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol. 2022;12:759306. doi:10.3389/fcimb.2022.759306.
   PubMed Web of Science ®Google Scholar
• Cheng S, Ma X, Geng S, Jiang X, Li Y, Hu L, Li J, Wang Y, Han X. Fecal microbiota transplantation beneficially regulates intestinal mucosal autophagy and alleviates gut barrier injury. mSystems. 2018;3(5):3. doi:10.1128/mSystems.00137-18.
   Web of Science ®Google Scholar
• Rao J, Xie R, Lin L, Jiang J, Du L, Zeng X, Li G, Wang C, Qiao Y. Fecal microbiota transplantation ameliorates gut microbiota imbalance and intestinal barrier damage in rats with stress-induced depressive-like behavior. Eur J Neurosci. 2021;53(11):3598–611. doi:10.1111/ejn.15192.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Sookoian S. Personalized medicine in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;28(4):935–8. doi:10.3350/cmh.2022.0175.
   PubMed Web of Science ®Google Scholar
• Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50(6):628–39. doi:10.1111/apt.15416.
   PubMed Web of Science ®Google Scholar
• Lang S, Schnabl B. Microbiota and fatty liver disease—the known, the unknown, and the future. Cell Host Microbe. 2020;28(2):233–244. doi:10.1016/j.chom.2020.07.007.
   PubMed Web of Science ®Google Scholar
• Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics - advances and challenges. Adv Drug Deliv Rev. 2016;105:44–54. doi:10.1016/j.addr.2016.04.032.
   PubMed Web of Science ®Google Scholar
• Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, Roberts SK. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023;17(5):1082–1097. doi:10.1007/s12072-023-10568-z.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-Järvinen H. International consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014 e1. doi:10.1053/j.gastro.2019.11.312.
   PubMed Web of Science ®Google Scholar
• Mahli A, Hellerbrand C. Alcohol and obesity: a dangerous association for fatty liver disease. Dig Dis. 2016;34(Suppl 1):32–39. doi:10.1159/000447279.
   PubMedGoogle Scholar